Overview
- Pfizer announced that Dave Denton will leave the company on August 15 and that Cecile Guegan will become interim chief financial officer on August 16, a move reported by multiple outlets on Thursday.
- Guegan is a more-than-20-year Pfizer finance veteran who led the 2024 financial integration of Seagen and will overlap with Denton to manage a handover.
- The stock fell roughly 3% after the announcement as analysts flagged risks to 2026 guidance and questioned the timing of a CFO change during a major strategic shift.
- Denton’s four-year tenure included heavy dealmaking funded in part by COVID-era vaccine and antiviral revenue, including the Seagen, Biohaven and Metsera acquisitions.
- Pfizer said it will run a comprehensive internal and external search for a permanent CFO, and investors should watch the company’s succession plan and how the finance team supports the coming obesity-drug launch.